Tili Esmerina, Michaille Jean-Jacques, Costinean Stefan, Croce Carlo M
Molecular Virology, Immunology and Medical Genetics Department, The Ohio State University, Columbus, OH 43210, USA.
Nat Clin Pract Rheumatol. 2008 Oct;4(10):534-41. doi: 10.1038/ncprheum0885. Epub 2008 Aug 26.
MicroRNAs (miRNAs) are short noncoding RNA molecules that modulate the expression of multiple target genes at the post-transcriptional level and are implicated in a wide array of cellular and developmental processes. In hematopoietic cells, miRNA levels are dynamically regulated during lineage differentiation and also during the course of the immune response. Mouse models have provided good evidence for miRNAs being key players in the establishment of hematopoietic lineages. Furthermore, miRNA-dependent alterations in gene expression in hematopoietic cells are critical for mounting an appropriate immune response to a wide range of pathogens, spontaneously emerging tumors, and autoimmune cells. Deregulation of hematopoietic-specific miRNA expression results in defects in both central and peripheral tolerance, hematopoietic malignancies, and sometimes both. Abnormal expression of miRNAs-which is implicated in inflammation-has also been found in patients with rheumatoid arthritis. These findings identify miRNAs as critical targets for immunomodulatory drug development.
微小RNA(miRNA)是短的非编码RNA分子,可在转录后水平调节多个靶基因的表达,并参与多种细胞和发育过程。在造血细胞中,miRNA水平在谱系分化过程中以及免疫反应过程中受到动态调节。小鼠模型为miRNA是造血谱系建立中的关键参与者提供了充分证据。此外,造血细胞中依赖miRNA的基因表达改变对于对多种病原体、自发出现的肿瘤和自身免疫细胞产生适当的免疫反应至关重要。造血特异性miRNA表达失调会导致中枢和外周耐受性缺陷、造血系统恶性肿瘤,有时两者都会出现。在类风湿性关节炎患者中也发现了与炎症相关的miRNA异常表达。这些发现将miRNA确定为免疫调节药物开发的关键靶点。